Загрузка...
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attenti...
Сохранить в:
Опубликовано в: : | J Clin Invest |
---|---|
Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
American Society for Clinical Investigation
2017
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5451217/ https://ncbi.nlm.nih.gov/pubmed/28504649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89548 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|